Novacyt S.A. ( (NVYTF) ) has released its Q4 earnings. Here is a breakdown of the information Novacyt S.A. presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Novacyt S.A. is an international molecular diagnostics company specializing in genomic medicine, offering a range of molecular assays and instrumentation for human, animal, and environmental health sectors. The company recently announced its full-year 2024 financial results, highlighting significant revenue growth driven by the acquisition of Yourgene Health. The company’s revenue for 2024 reached £19.6 million, marking an 85% increase year-over-year, primarily due to the Yourgene acquisition. Key growth areas included reproductive health and Ranger Technology consumables, while Primer Design’s sales remained stable. Despite the revenue growth, Novacyt reported a loss after tax of £41.8 million, influenced by exceptional charges and integration costs. The company successfully delivered £5.0 million in cost synergies from the Yourgene acquisition ahead of schedule and is on track to achieve further EBITDA improvements through site consolidations. Looking forward, Novacyt plans to invest in high-priority growth areas, with a focus on launching new products in 2025. The management remains confident in achieving EBITDA profitability through continued cost reductions and revenue growth from both existing and new products.